ArticleFrontiers in pharmacology2026
Optimization of individualized therapy with oral valproic acid in pediatric patients with epilepsy based on factors influencing blood concentrations.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Valproic acid (VPA) is widely used in pediatric epilepsy, but its blood concentrations vary considerably among pediatric patients with epilepsy. This study aimed to investigate the factors influencing VPA blood concentrations in this population. Methods: This study included patients with epilepsy aged 0-18 years who were treated with VPA. Clinical data collected included age, gender, daily dose, biochemical parameters (liver and renal function), and electrolyte levels. VPA blood concentrations were measured by immunoassay. Correlation analyses and linear regressions were conducted to assess associations between clinical variables and VPA blood concentrations. Results: The mean VPA blood concentration was 69.82 ± 25.22 μg/mL, and 70.06% of patients had blood concentrations within the therapeutic range. Daily dose was positively correlated with blood concentration ( Conclusion: VPA blood concentrations in the study population were influenced by multiple factors, including daily dose, age, renal and hepatic function, and electrolyte status. Given the marked inter-individual variability, individualized treatment guided by therapeutic drug monitoring (TDM) is essential for optimizing dosing accuracy and therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.